XML 24 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Marketable Securities – InterCure Ltd
 12 Months Ended
Dec. 31, 2023
Marketable Securities – InterCure Ltd [Abstract]  
MARKETABLE SECURITIES – InterCure Ltd
NOTE 6:MARKETABLE SECURITIES – InterCure Ltd

 

a.All marketable securities held by the Company constitute Level 1 financial instruments, as defined in IFRS 13 - “Fair Value Measurement”. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date.

 

b.The Company holds the following financial instruments:

 

   December 31, 
   2023   2022 
   U.S. dollars in thousands 
         
Marketable securities - InterCure Ltd   605    1,627 

 

The entire investment in marketable securities is classified as a financial asset at fair value through profit or loss. As of December 31, 2023 and 2022 the Company holds approximately 1.04% of InterCure Ltd’s shares (the shares are traded at the Tel-Aviv Stock Exchange - “TASE” and at the Nasdaq Capital Market - “Nasdaq”).

 

c.Changes in marketable securities for the years ended December 31, 2023, 2022 and 2021, were as follows:

 

   December 31, 
   2023   2022   2021 
   U.S. dollars in thousands 
             
Fair value opening balance   1,627    3,158    2,411 
Changes in fair value during the year   (1,022)   (1,531)   747 
                
Fair value closing balance   605    1,627    3,158